With the Synthes acquisition done and Zytiga on the market, I don't think Johnson & Johnson (JNJ)
investors should expect too much additional flash in 2013. That may not
be such a bad thing, though, as this is a pretty good company that
would benefit from some serious "back to basics" operational
improvements. J&J is also looking like a like relative bargain, with
good growth in pharmaceuticals and opportunity for improved results in
the device business.
Click here to continue:
Johnson & Johnson Looks To Get Ahead With Blocking And Tackling
No comments:
Post a Comment